Transdermal Formulations Assessment

Overview

A leading global pharmaceutical company needed to license six transdermal formulations for existing products available in oral form. The transdermal form had fewer side effects and required lower dosage. Harrison Hayes was to assess the market receptivity for this new delivery system.

Our Solution

Results

As a result of the comparative analysis, the client successfully completed the transaction and launched the first two optimal candidates in this study.